目的 探讨通心络对急性冠脉综合征(acute coronary syndrome, ACS)患者PCI术后炎性反应及血管内皮功能的影响。方法 收集辽河油田总医院心内科2017-10至2018-03收治的拟行PCI治疗的ACS住院患者137例,以随机信封法分为通心络组(68例)和对照组(69例)。对照组给予冠心病常规治疗,通心络组在常规治疗的基础上给予通心络胶囊口服治疗,观察周期均为12周。监测两组PCI术后血管生成素样蛋白2(Angptl2)、白细胞介素(IL)-18及血浆纤溶酶原激活物抑制剂-1(PAI-1)水平变化,术后12周肱动脉血管内皮舒张功能(FMD)和小动脉弹性指数(C2)。结果 观察治疗12周后,两组Angptl2[(27.61±8.55)ng/L,(32.30±11.56)ng/L]及IL-18[(75.66±10.22)pg/ml,(91.81±12.99)pg/ml]水平均较治疗前[(61.95±10.31)ng/L,(60.83±10.00)ng/L;(178.28±12.00)pg/ml,(180.12±10.43)pg/ml]显著降低(P＜0.05),同时PAI-1水平[(26.64±8.0)μg/L,(30.92±6.64)μg/L]较治疗前[(88.71±8.11) μg/L,(83.33±8.70) μg/L]显著降低(P＜0.05);且通心络组Angptl2及IL-18水平较对照组显著降低(P＜0.05);通心络组PAI-1水平低于对照组,两组间差异有统计学意义(P＜0.05)。治疗12周后两组FMD和C2均有改善,通心络组[FMD(8.99±1.12),C2(6.32±0.70) ml/mmHg×100]水平明显优于对照组[(6.65±0.95),(5.42±0.91)ml/mmHg×100]) (P＜0.05)。结论 通心络可通过降低Angptl2、IL-18、PAI-1水平及改善FMD和C2,减轻ACS患者PCI术后炎性反应、恢复血管内皮功能和修复小动脉弹性。
Abstract
Objective To study the effects of Tongxinluo on inflammation, endothelial function and artery elasticity in patients with acute coronary syndrome (ACS).Methods One hundred and thirty-seven patients who were diagnosed with ACS and prepared for PCI between October 2017 and March 2018 were selected as the subjects. They were randomly divided into the Tongxinluo group (n=68) and control group (n=69). Levels of Angptl2, IL-18, and PAI-1 in plasma were measured using ELISA methodology after admission and during the 12-week follow-up. The brachial artery flow-mediated dilation (FMD) and C2 were also calculated at the same time points and compared between the two groups.Results After 12-week follow-up, the levels of serum Angptl2, IL-18, and PAI-1 in the Tongxinluo group were (27.61±8.55) ng/L, (75.66±10.22) pg/mL and (26.64±8.00) μg/L respectively, which were lower than (32.30±11.56) ng/L, (91.81±12.99) pg/mL and (30.92±6.64) μg/L in the control group (P<0.05). Patients in the Tongxinluo group had higher levels of FMD (8.99±1.12) and C2 (6.32±0.70) ml/mmHg×100 than those [(6.65±0.95;5.42±0.91) mL/mmHg×100] in the control group (P<0.05).Conclusions Tongxinluo capsules can reduce inflammation, restore the endothelial function and arterial elasticity in ACS patients.
关键词
急性冠脉综合征 /
PCI术 /
炎性反应 /
血管内皮功能
Key words
acute coronary syndrome /
PCI /
inflammation /
endothelial function
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases[J]. FEBS J, 2011, 278 (4):559-564.
[2] Grzegorzewska A E,Ostromecki G,Zielińska P,et al.T-cell cytokine gene polymorphisms and vitamin D pathway gene polymorphisms in end-stage renal disease due to type 2 diabetes mellitus nephropathy: comparisons with health sta-tus and other main causes of end-stage renal disease[J].J Diabetes Res, 2014, 2014: 120317.
[3] Scarabin P Y, Arveiler D, Amouyel P, et al. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study[J]. Atherosclerosis, 2003, 166(1):103-109.
[4] 孤竹国. 2011ACC /AHA 非 ST 段 抬 高 型 急 性 冠 脉 综 合 征(NSTACS) 指南与ESC NSTACS指南的比较[J].中国全科医学,2012,15(8):829-830.
[5] Bianchini E, Faita F, Gemignani V, et al. The assessment of flow-mediated dilation (FMD) of the brachial artery[J]. Comput Cardiol, 2016, 43(5): 509-512.
[6] 姜智多,蒋 捷,黄延平,等.不同剂量阿托伐他汀对老年冠心病合并高脂血症患者的临床疗效和安全性分析[J].医学综述,2015,21(7): 1312-1314.
[7] Fichtlscherer S, Breuer S, Zeiher A M. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "Vulnerable" patient [J]. Circulation, 2014, 110(14):1926-1932.
[8] Libby P. Inflammation in atherosclerosis [J]. Nature, 2012, 420(6917):868-874.
[9] Depre C, Wijins W, Robert A M, et al. Pathology of unstable plaque correlation with the clinical severity of acute coronary syndromes [J]. Am J Coll Cardiol, 1997, 30(3): 694-702.
[10] 王志清,黄明方,罗助荣,等. 血管生成素样蛋白2与心血管疾病的研究进展[J].心血管病学进展,2014,35(1): 75-78.
[11] Horio E,Kadomatsu T,Miyata K,et al. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression[J]. Arterioscler Thromb Vasc Biol,2014,34(4):790-800.
[12] Xing Y,Tian Y,Kurosawa T,et al. Inhibition of blood vessel formation in tumors by IL-18 polarized M1 macrophages [J].Genes Cells,2016,21(3) : 287-295.
[13] WANG Jing,SUN Chongxiu,GERDES N, et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter [J]. Nat Med,2015,21(7) : 820-826.
[14] Kaptoge S,Seshasi S R,Gao Pei,et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis [J] Eur Heart J,2014,35(9) : 578-589.
[15] 纪瑞锋,袁 媛,刘 娟.人参叶与人参化学及药理活性差异分析[J]. 中华中医药杂志,2017,32(5): 2269-2271.
[16] 包钰婷,郭在培,王小雪,等.芍药苷抗氧化应激机制研究进展[J].中国麻风皮肤病杂志,2017,33(6): 374-377.
[17] 李大鹏,孙党辉,张春茹,等.通心络胶囊对自发性高血压大鼠血管内皮功能和炎症机制影响研究[J].实用医院临床杂志,2017,14(4): 241-243.
[18] 董彦文,牧 骑,祁 宏,等.通心络胶囊对糖尿病急性心肌梗死患者PCI 术后炎症因子及血管内皮功能的影响[J].中国医师杂志,2013,15(5): 704-706.
[19] 李 媛,田文华,张桂侠,等.通心络胶囊对急性冠脉综合征可溶性细胞间粘附分子-1和C反应蛋白水平的影响[J].实用中医药杂志,2016, 32(9): 850-852.
[20] 张晓东.通心络胶囊合并替米沙坦对高血压患者血管内皮功能和氧化应激的影响[J].中国循证心血管医学杂志,2016,8(3): 364-366
[21] Vaes A W, Spruit M A, Theunis J, et al. Endothelial function in patients with chronic obstructive pulmonary disease: a systematic review of studies using flow mediated dilatation[J]. Expert Rev Respir Med, 2017, 11(12): 1-11.
PDF(730 KB)
